| | View this message online 
Hello manoj kumar valluru, An interesting patent, # 7,459,307, was issued last week covering the use of cord blood stem cells together with biodegradable scaffolds for treatment of cartilage injury. Vet-Stem has created a profitable business through using autologous fat for treatment of similar conditions. This will be an interesting area to watch, especially for high-performance athletes. Another patent, #7,462,602, covers the use of ribozymes for inhibition of scar tissue formation. The ribozymes target connective tissue growth factor (CTGF). In the news, the first time in the world, autologous stem cells were administered via the intracoronary route to a 2-year old patient with heart failure caused by dilated cardiomyopathy. | | Patent Number: 7,459,307 Cord blood derived stem cells represent a potent source of young, pluripotent, cells. Although previously their use was restricted to hematological malignancies, newer studies have demonstrated cord blood cells may be useful for many regenerative purposes, such as Ethicon's patent #7,413,734 which teaches... [Read More] Ask a question OR leave your comments. | | |
The 3rd Annual Stem Cells World Congress (20-22 January 2009)
The Stem Cell Meeting (March 2009)
| | NEWS - WHAT'S GETTING ATTENTION? | | |
Thanks again for your help in supporting StemCellPatents.com.
We welcome your comments and suggestions! Tell us here.
Media Partnerships (NEW)
NEW -  (BETA) Now you can send our newsletters to your friends and colleagues using our quick and easy send-to-a-friend feature (BETA).
------------------------------------------------------------ To unsubscribe, click here. Delivered: Tuesday December 16th, 2008 @ 14:25:23 EST | |
